Oppenheimer Begins Coverage on InflaRx (NASDAQ:IFRX)

Oppenheimer assumed coverage on shares of InflaRx (NASDAQ:IFRX) in a report released on Thursday,Benzinga reports. The brokerage issued an outperform rating and a $6.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Guggenheim raised their price target on InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 26th. Finally, Cantor Fitzgerald assumed coverage on shares of InflaRx in a research report on Tuesday, April 29th. They set an “overweight” rating and a $10.00 price objective for the company.

InflaRx Price Performance

InflaRx stock opened at $1.61 on Thursday. InflaRx has a fifty-two week low of $0.82 and a fifty-two week high of $2.82. The firm has a market capitalization of $108.08 million, a PE ratio of -1.49 and a beta of 1.57. The company’s 50-day moving average is $1.23 and its 200-day moving average is $1.82.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, analysts expect that InflaRx will post -1.04 EPS for the current year.

Institutional Investors Weigh In On InflaRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of InflaRx during the first quarter valued at about $38,000. Cubist Systematic Strategies LLC bought a new position in shares of InflaRx in the 4th quarter worth about $55,000. Northern Trust Corp lifted its stake in InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock valued at $1,647,000 after buying an additional 634,045 shares during the period. Two Sigma Securities LLC bought a new position in InflaRx during the fourth quarter worth $28,000. Finally, Walleye Capital LLC acquired a new stake in shares of InflaRx in the 4th quarter valued at about $51,000. 42.39% of the stock is owned by institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.